<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">128</article-id><article-id pub-id-type="doi">10.36233/0372-9311-2017-1-86-96</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">PRINCIPLES OF MONITORING OF ADVERSE EVENTS AFTER VACCINATION IN RUSSIAN FEDERATION AND THE WORLD</article-title><trans-title-group xml:lang="ru"><trans-title>ПРИНЦИПЫ МОНИТОРИНГА НЕБЛАГОПРИЯТНЫХ СОБЫТИЙ ПОСЛЕ ВАКЦИНАЦИИ В РОССИИ И В МИРЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nacharova</surname><given-names>E. P.</given-names></name><name xml:lang="ru"><surname>Начарова</surname><given-names>Е. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kharit</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Харит</surname><given-names>С. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lobzin</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Лобзин</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Briko</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Брико</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Childrens’ Infections</institution></aff><aff><institution xml:lang="ru">НИИ детских инфекций</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М.Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-02-28" publication-format="electronic"><day>28</day><month>02</month><year>2017</year></pub-date><volume>94</volume><issue>1</issue><issue-title xml:lang="ru"/><fpage>86</fpage><lpage>96</lpage><history><date date-type="received" iso-8601-date="2019-04-10"><day>10</day><month>04</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Nacharova E.P., Kharit S.M., Lobzin Y.V., Briko N.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Начарова Е.П., Харит С.М., Лобзин Ю.В., Брико Н.И.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Nacharova E.P., Kharit S.M., Lobzin Y.V., Briko N.I.</copyright-holder><copyright-holder xml:lang="ru">Начарова Е.П., Харит С.М., Лобзин Ю.В., Брико Н.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/128">https://microbiol.crie.ru/jour/article/view/128</self-uri><abstract xml:lang="en"><p>Difference in terminology accepted in our and foreign countries for designating disease of post-vaccination period is shown. Analysis of the existing regulating documents in Russian Federation regarding registration of adverse events in post-vaccination period and system of registration accepted in many countries of the world and recommended by WHO is presented. In Russian Federation in accordance with the documents of the Federal Service of Surveillance for Protection of Consumers Rights and Human Welfare only certain conditions (post-vaccinal complications) are subject to registration. In accordance with WHO recommendations all adverse events taking place 1 month after the vaccination must be registered. Summarization of these data allows to detect interconnection between these conditions and vaccination or prove the lack thereof.</p></abstract><trans-abstract xml:lang="ru"><p>Показана разница в терминологии, принятой в нашей стране и зарубежом, для обозначения заболеваний поствакцинального периода. Представлен анализ существующих регламентирующих документов в РФ по вопросу регистрации неблагоприятных событий в поствакцинальном периоде и системы регистрации, принятой во многих странах мира и рекомендованной ВОЗ. В Российской Федерации согласно документам Роспотребнадзора обязательной регистрации подлежат только отдельные состояния (поствакцинальные осложнения). Согласно рекомендациям ВОЗ должны регистрироваться все неблагоприятные события в течение 1 месяца после вакцинации. Обобщение этих данных позволяет выявить взаимосвязь этих состояния с вакцинацией или доказать ее отсутствие.</p></trans-abstract><kwd-group xml:lang="en"><kwd>post-vaccinal period</kwd><kwd>adverse events</kwd><kwd>post-vaccinal complications</kwd><kwd>inter-current diseases</kwd><kwd>vaccination</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>поствакцинальный период</kwd><kwd>неблагоприятные события</kwd><kwd>поствакцинальные осложнения</kwd><kwd>интеркуррентные заболевания</kwd><kwd>вакцинация</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Григорьев К. И. Корь: что впереди - ликвидация инфекции или эпидемия? Медицинская сестра. 2012, 7:9-13.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Лакоткина Е.А., Харит С.М., Черняева Т.В. и др. Поствакцинальные осложнения (клиника, диагностика, лечение, профилактика): Пособие для практического врача. М., 2004.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Лыткина И.Н., Заволжских А.М. Современные особенности эпидемиологии коревой инфекции в условиях мегаполиса. Педиатрия. 2013, 1: 15-17.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Львова И.И., Фельдблюм И.В., Корюкина И.П. и др. Мониторинг событий поствакцинального периода. Эпидемиология и инфекционные болезни. 2004, 5: 2-14.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Методические указания МУ 3.3.1.1123-02 3.3.1. Вакцинопрофилактика. Мониторинг поствакцинальных осложнений и их профилактика. Методические указания (утв. Главным государственным санитарным врачом РФ 26.05.2002). http://www.consultant. ru/document/cons_doc_LAW_100503/.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Методические указания МУ 3.3.1879-04. Расследование поствакцинацльных осложнений (утв. главным государственным санитарным врачем РФ 04.03.2004). http://www. hrsa.gov/vaccinecompensation/data/statisticsreport.pdf.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Семенов Б.Ф., Лябис О.И., Михайлова Н.А. Основные этапы развития вакцинологии и вакцинопрофилактики. Вакцины и вакцинация: Национальное руководство. Под ред. В.В. Зверева, Б.Ф. Семенова, Р.М. Хаитова. М., ГЭОТАР-Медиа, 2011, с. 18-25.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Тихонова Н.Т., Герасимова А.Г., Цвиркун О.В. и др. Причины роста заболеваемости корью в России в период элиминации инфекции. Педиатрия. 2013,1: 9-14.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Учайкин В.Ф., Шамшева О.В. Вакцинопрофилактика: настоящее и будущее. М., 2006.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Харит С.М. Вакцинопрофилактика: проблемы и перспективы. Журн. инфектологии. 2009,1 (1): 61-65.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Харит С.М., Черняева Т.В., Лакоткина Е.А. Структура заболеваний поствакцинального периода (анализ наблюдений за 40 лет). Эпидемиология и вакцинопрофилактика. 2010, 2 (51): 64-69.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ясинский А.А. Законодательные аспекты вакцинопрофилактики. Вакцины и вакцинация: Национальное руководство. Под ред. В.В.Зверева, Б.Ф.Семенова, Р.М.Хаитова. М., ГЭОТАР-Медиа, 2011, с. 826-831.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ясинский А.А., Михеева И.В. Безопасность иммунизации. Вакцины и вакцинация: Национальное руководство. Под ред. В.В. Зверева, Б.Ф. Семенова, Р.М. Хаитова. М., ГЭОТАР-Медиа, 2011, с. 137-162.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Asatryan A., Pool V., Chen R.T. et al. Live attenuated measles and miumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990 - 2003. Vaccine. 2008, 26 (9): 1166-1172.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bonhoeffer J., Zumbrunn B., Heininger U. Reporting of vaccine safety data in publications: systematic review. Pharmacoepidemiol. Drug Saf. 2005, 14 (2): 101-106.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Boyd S.D., Jackson K.J. Predicting vaccine responsiveness. Cell. Host. Microbe. 2015, 17 (3): 301-307.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Boyman O., Comte D., Spertini F. Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol. 2014, 10 (10): 612-627.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cashman R, Moberley S., Dalton C. et al. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014, 32 (42): 5503-5508.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Centers for Disease Control and Prevention (CDC). Syncope after vaccination - United States, January 2005-July 2007. MMWR. 2008, 57 (17): 457-460.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Crawford N.W., Clothier H., Hodgson K. et al. Active surveillance for adverse events following immunization. Expert. Rev. Vaccines. 2014, 13 (2): 265-276.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fine P. Science and society: vaccines and public health. Public Health. 2014, 128 (8): 686-692.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Global Advisory Committee on Vaccine Safety (GACVS); WHO secretariat. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert. Rev. Vaccines. 2009, 8 (6): 705-716.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R. Soc. bond. B. Biol Sci. 2014, 369 (1645): 20130433.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Haber P., Iskander J., Walton K. et al. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics. 2011, 127 (Suppl. 1): 39-44.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Halsey N.A., Edwards K.M., Dekker C.L. et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine. 2012, 30 (39): 5791-5798.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Huang Y.L., Moon J., Segal J.B. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014, 37 (8): 581-596.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Jarrett C., Wilson R., O'Leary M. et al. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015, 33 (34): 4180-4190.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Jones P.G., Cowan G., Gravendyck M. et al. Regulatory requirements for vaccine authorisation. Rev. Sci. Tech. 2007, 26 (2): 379-393.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Lawrence G., Gold M.S., Hill R. et al. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun. Dis. Intell. Q. Rep. 2008, 32 (4): 371-387.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Leca M., Bomet C, Montana M. et al. Meningococcal vaccines: Current state and future outlook. Pathol. Biol. (Paris). 2015, 63 (3): 144-151.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Lee C.J., Lee L.H., Lu C.H. Safety monitoring in vaccine development and immunization. Acta Paediatr. Taiwan. 2006, 47 (1): 7-13.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Leeb A., Regan A.K., Peters I.J. etal. Using automated text messages to monitor adverse events following immunisation in general practice. Med. J. Aust. 2014, 200 (7): 416-418.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Lopalco P.L., Johansen K., Ciancio B. Monitoring and assessing vaccine safety: a European perspective. Expert. Rev. Vaccines. 2010, 9 (4): 371-380.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Maglione M.A., Das L., Raaen L. et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014, 134 (2): 325-337.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>McNeil M.M., Gee J., Weintraub E.S. et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014, 32 (42): 5390-5398.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Muehlhans S., Richard G., Ali M. et al. Safety reporting in developing country vaccine clinical trials-a systematic review. Vaccine. 2012, 30 (22): 3255-3265.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>National Vaccine Injury Compensation Program Data Report - March 1, 2016.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Niu M.T., Ball R., Woo E.J. et al. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine. 2009, 27 (2): 290-297.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Parez N., Giaquinto C, Du Roure C. et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect. Dis. 2014, 14 (5): 416-425.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Rappuoli R., Pizza M., Del Giudice G. et al. Vaccines, new opportunities for a new society. Proc. Nat. Acad. Sci. USA. 2014, 111 (34), 6: 12288-12293.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Schuster M., Eskola J., Duclos P. et al. Review of vaccine hesitancy: Rationale, remit and methods. Vaccine. 2015, 33 (34): 4157-4160.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>ShimabukuroT.T., Nguyen M., Martin D. et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015, pii: S0264-410X( 15)00982-2.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Soriano A., Nesher G., Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol. Res. 2015, 92: 18-22.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Thoon K.C., Soh S.B., Liew W.K. et al. Active surveillance of adverse events following childhood immunization in Singapore. Vaccine. 2014, 32 (39): 5000-5005.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Tozzi A. E., Asturias E.J., Balakrishnan M.R. et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013, 31 (44): 5041-5046.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>William S.E., Barlow Ph.D., Robert L. Davis et al. The risk of seizures after receipt of wholecell pertussis or measles, mumps, and rubella vaccine. For the Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The New England Journal of Medicine. 2001,345:656-661.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Williams S.E., Klein N.P., Halsey N. et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine. 2011, 29 (40): 6920-6927.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Woo E.J., Wise R.P., Menschik D. et al. Thrombocytopenia after vaccination: case reports to the US vaccine adverse event reporting system, 1990 - 2008. Vaccine. 2011, 29: 1319-1323.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Yaqub O., Castle-Clarke S., Sevdalis N. et al. Attitudes to vaccination: a critical review. Soc. Sci. Med. 2014, 112:1-11.</mixed-citation></ref></ref-list></back></article>
